As a result of chromosome translocations, the EWS gene is fused to a variety of transcription factors in human solid neoplasia. In Ewing tumors EWS can be fused to four dierent members of the ETS family, namely FLI-1, ERG, ETV1 and E1AF. We have identi®ed a new member of the ETS family, called FEV, which is fused to EWS in a subset of Ewing tumors. FEV encodes a 238 amino acid protein which contains an ETS DNA binding domain closely related to that of FLI-1 and ERG. However, the N-terminal portion of FEV is only 42 amino acids long which suggests that FEV is lacking important transcription regulatory domains contained in FLI-1 and ERG N-terminal parts. The C-terminal end of FEV is rich in alanine residues which may indicate that FEV is a transcription repressor. The FEV gene is encoded by three exons and is located on chromosome 2. FEV expression was only detected in adult prostate and small intestine but not in other adult nor in fetal tissues, thus indicating that FEV has a restricted expression pattern. Following a scheme similar to previously described translocations in Ewing tumors, a t(2;22) chromosome translocation fuses the N-terminal domain of EWS to the ETS DNA binding domain of FEV.
Introduction
The ETS family of proteins is composed of an increasing number of transcription factors which are involved in a variety of developmental processes and cellular responses to external stimuli. ETS family members are de®ned by the presence of a highly conserved 85 amino acids domain termed the ETS domain which mediates speci®c binding to DNA purine rich sequences characterized by an invariant GGA/TA core element (Wasylyk et al., 1993) .
Numerous members of the ETS family have been shown to be involved in oncogenesis both in animals and in humans. v-ets1, the ®rst identi®ed member of this family, was originally discovered as part of the gag-myb-ets transforming component of the E26 retrovirus which induces erythroleukemias in chicken (Leprince et al., 1983; Nunn et al., 1983) .
Fli-1 and Spi-1/PU1 transcriptions are activated by retroviral integration in most murine erythroleukemias induced by the Friend and spleen focus-forming viruses, respectively (Moreau-Gachelin et al., 1988; Ben-David et al., 1991) .
In humans, several ETS members are fused to a variety of partners through chromosome translocations. The TEL gene on chromosome 12 is involved in at least four dierent leukemia associated rearrangements (Golub et al., 1994 (Golub et al., , 1995 Papadopoulos et al., 1995; Romana et al., 1995; Buijs et al., 1995) .
Dierent ETS DNA binding domains are fused with the N-terminal domain of the EWS RNA binding protein as a result of a variety of translocations observed in the Ewing family of tumors (EFT). The EFT constitutes a spectrum of aggressive bone and soft tissue neoplasia appearing most frequently as undifferentiated small round cell tumors (Horowitz et al., 1993) . Most tumors are characterized by a balanced and reciprocal t(11;22)(q24;q12) chromosome translocation which fuses the chromosome 22 EWS gene to the FLI-1 gene on chromosome 11 (Delattre et al., 1992) . The EWS/FLI-1 fusion gene encodes a chimeric protein in which the N-terminal domain of EWS rich in serine, glutamine and tyrosine is fused to the Cterminal DNA binding domain of FLI-1. The EWS/ FLI-1 chimeric protein acts as a more potent transcription activation factor than FLI-1 on reporter genes containing ETS binding sites May et al., 1993; Bailly et al., 1994) and can promote cell transformation when overexpressed in NIH3T3 cells (May et al., 1993) . Both EWS and FLI-1 portions appear necessary to mediate these eects. In approximately 10% of Ewing tumors (ET) EWS is fused to the ERG gene through a t(21;22) chromosome translocation (Zucman et al., 1993a; Sorensen et al., 1994) . This same ERG gene can also be fused to TLS, a gene homologous to EWS, as a result of a t(16;21)(p11;q22) translocation observed in some acute myeloid leukemias (Ichikawa et al., 1994) . Finally, in rare cases of ET, fusion of EWS occurs with either the ETV1 gene on chromosome 7 or the E1AF gene on chromosome 17 (Jeon et al., 1995; Kaneko et al., 1996) .
We have now analysed an ET characterized by a complex t(2;21;22)(q33;q22;q12) chromosome translocation. This translocation involves on chromosome 2 a previously unknown member of the ETS family.
Results

A new gene fusion detected in two Ewing tumors
Cytogenic analysis of cells from the MOU tumor demonstrated the presence of a complex t(2;21;22)(q33;q22;q12) chromosome translocation (Couturier et al. in preparation). The involvement of chromosome 21 and 22 in this translocation suggested that the ERG and EWS genes might be fused. RNAs were isolated from tumor cells and subjected to RT ± PCR ampli®cations of the expected EWS-ERG fusion with primers 22.14/ERG11 and of the normal EWS transcript with primers 22.14/22.15 (Table 1) . Although the control ampli®cation of EWS was strongly positive, indicating that RNAs were not degraded, attempts to amplify an EWS-ERG fusion yielded a very low amount of ampli®cation products which could be detected only after Southern blotting and hybridization with the 22.3 internal primer ( Figure 1a ). This suggested that a gene homologous to either ERG or EWS might be involved in this fusion. This hypothesis was further supported by the observation that the amount of PCR products increased when the annealing temperature of PCR was reduced from 688C to 628C. PCR products obtained under low stringency PCR conditions were puri®ed and sequenced. This revealed that the sequence of EWS exon 10 was linked, in frame, to a new sequence, homologous but distinct from ERG. This sequence was termed FEV for Fifth Ewing Variant. The knowledge of this sequence permitted to develop a more direct assay to test for the presence of an EWS-FEV fusion using FEV and EWS speci®c primers (Figure 1b) . In addition to this PCR analysis, independant con®rmation of the involvement of EWS was provided by the detection of rearranged fragments after hybridization of a Southern blot made with MOU tumor DNA with the RX.4 probe from the EWSR1 region ( Figure 1c ) (Zucman et al., 1993a) . The PCR strategy which was used to amplify EWS-FEV together with the sequence of the junction is shown on Figure 1d .
FEV and EWS speci®c primers were used to screen for EWS-FEV fusions a series of 10 RNAs isolated from small round cell tumors diagnosed as ET but lacking EWS-FLI-1, ERG, ETV1 or E1AF fusion transcripts. It was possible to amplify a speci®c 
22.14/ERG 11 22.14/ERG 11, FEV11 product from one of these tumor RNAs (AUB). Sequencing of this product revealed an identical EWS-FEV fusion as that observed in the MOU tumor, the only dierence being the presence of a C instead of a T at the ®rst position of codon 348 of EWS encoding a leucine, a previously shown polymorphism of EWS.
Characterization of the normal FEV gene
In order to clone the normal counterpart of the FEV gene, RNAs from cell lines (neuroblastoma and ET cell lines), tumors (breast, ovary, lung, colon, kidney, adrenocortical carcinomas; leukemia; lymphoma; neuroblastomas) and tissues (kidney, muscle, lymphocytes, ®broblasts, adrenal cortex) were screened for FEV expression by RT ± PCR with Primers M3 and F1 (Table 1) . A speci®c ampli®cation product was observed in all neuroblastoma samples and in most ETs cell lines. RNAs from other sources were negative indicating that the expression of FEV is restricted to few cell types. Given these data, a total of 10 6 lambda gt11 phages from a Ewing speci®c cDNA library were screened with the 32 P-labeled M3/F1 PCR product. Five positive clones were retrieved and cloned in the M13 vector. Sequencing of these cDNAs showed that they were overlapping over approximately 1.2 kb and that they had all been oligodT primed since they contained a polyA tract of various lengths 15 bp from a ATTAAA putative polyadenylation signal (Figure 2a) . The sequence of the longest clone, STAFEV1, revealed a 717 bp open reading frame initiating with a methionine in the context of a putative Kozak sequence (purine at position 73 and +1).
To further con®rm that the 5' end of the STAFEV1 cDNA corresponded to that of the FEV gene and could not be related to a cloning artefact, two types of experiments were conducted. Firstly, primers FL and FLRB (Table 1; Figure 2a ) were used for RT ± PCR ampli®cation of RNAs from four neuroblastoma samples. In each case, the expected 805 bp fragment was observed demonstrating that FL and FLRB sequences were contiguous on the same mRNA molecule and thus ruling out the hypothesis of the STAFEV1 cDNA being a chimeric clone. Secondly, these same primers were used for long range PCR on genomic DNA. They enabled the ampli®cation of an approximately 3.5 kb fragment. Sequence of this fragment indicated the presence of two introns. This further con®rmed genomic colinearity of the 5' and 3' end of the STAFEV1 clone. Finally, PCR ampli®cation Figure 2a ) demonstrated that the ETS domain and the C-terminal part of FEV are encoded by a single exon. Altogether, these experiments showed that the FEV gene is composed of three exons. Schematic representation of the genomic organisation of the FEV gene and sequences of the intron-exon junctions are indicated in Figure 3 . The position of the fusions between EWS and FEV sequences in the MOU and AUB cases suggests that the translocation breakpoints of these tumors occurred within intron 1 of FEV (Figure 2b) .
The peptide sequence of FEV demonstrates particular features. The ETS DNA binding domain is most closely related to that of FLI-1 (Figure 2c ). The Cterminal end of FEV is characterized by a 112 amino acid domain rich in alanine, proline, leucine and glycine which includes a continuous stretch of 12 alanines (Figure 2b ). The N-terminal part of FEV from the initiating methionine codon to the ETS domain is only 42 amino acid long.
Expression pattern and chromosome localization of FEV
In order to document more precisely the expression pattern of FEV, a FEV cDNA probe was used for hybridization experiments on Northern blots made from various adult and fetal tissues. A speci®c signal was observed only in adult prostate and small intestine but not in other adult or fetal tissues (Figure 4) . Finally, to de®ne the chromosome localization of FEV, DNA from somatic cell hybrids was used as template for PCR ampli®cation with FJ and FK primers (Table 1; Figure 2a) . A speci®c ampli®cation product was observed only in the hybrid cell line containing human chromosome 2 indicating that FEV is localized on this chromosome and thus con®rming that the EWS/FEV fusion arises through a t(2;22) chromosome translocation.
Discussion
We have characterized a new t(2;22) translocation which is observed in ET. This translocation results in the fusion of EWS on chromosome 22 with a previously unknown member of the ETS family located on chromosome 2. Among the Ewing family of tumors, the two cases described here with an EWS-FEV fusion do not appear to have evident speci®c pathological features. However, in both cases, the tumors arose in soft tissue, a localization which is observed more rarely than in bone among ETs. Identi®cation of additional cases should determine whether soft tissue localization is a common feature of tumors with an EWS-FEV fusion. The frequency of this translocation among ETs appears to be rare. Indeed, in our series of more than 200 ETs, only two expressed an EWS-FEV fusion. This permits an estimation of the frequency of the EWS-FEV fusion at around 1% of ETs.
Phenotypically, ETs are frequently dicult to distinguish from other small round cell tumors, namely rhabdomyosarcoma, lymphoma, neuroblastoma and rarer entities (Horowitz et al., 1993) . RT ± PCR detection of EWS-FLI-1 and EWS-ERG fusions has provided a simple and relevant diagnostic test Giovannini et al., 1994; Zoubec et al., 1994) . The recognition of rarer fusions such as those involving ETV1, E1AF or FEV is necessary to further improve the reliability and the sensitivity of this diagnostic test. A search for these fusions can now be easily included in routine multiplex RT ± PCR analysis. The EFT constitutes a spectrum of tumors which can exhibit a range of phenotypes (Horowitz et al., 1993) . Variable traits are mainly tissue localization, size of the cells and possible expression of neural markers. Interestingly, this family also demonstrates a variety of related but distinct genotypic markers. Long term follow-up of the patients and analysis of a larger series should permit a study of possible genotype-phenotype correlations.
FEV is a new member of the ETS family of transcription factors. Among this family, its DNA binding domain is more closely related to the FLI-1/ ERG subgroup. This strongly suggests that EWS-FEV may alter the transcription of similar target genes than EWS-FLI-1 or EWS-ERG. However, apart from the DNA binding domain, FEV demonstrates unique features. FLI-1 and ERG have large N-terminal domains which are involved in transcription regulation. In particular these domains have been shown to promote transcription activation of reporter genes containing ETS binding sites (Reddy and Rao, 1991; Zhang et al., 1993; Rao et al., 1993; Klemsz et al., 1993) . The absence of an N-terminal domain in FEV suggests that this protein does not share the transcriptional activation properties of FLI-1 and ERG. Moreover, the high content in alanine residues of the C-terminal part of FEV, a feature which has been observed in various transcription repressors (Yeung et al., 1994) , may indicate that FEV is a repressor of the FLI-1/ERG subfamily. The fusion of FEV sequences with the Gal4 DNA binding domain and the cloning of FEV in expression vectors should enable this hypothesis to be tested.
FEV is the ninth fusion partner of EWS observed in tumors. Indeed, in addition to fusion with FLI-1, ERG, ETV1 and E1AF in ET, the 5' part of EWS can be linked to ATF1 in malignant melanoma of soft parts, to WT1 in desmoplastic small round cell tumors, to TEC/CHN in extraskeletal myxoid chondrosarcoma and to CHOP in myxoid liposarcoma (Zucman et al., 1993b; Ladanyi and Gerald, 1994 Labelle et al., 1995; Clark et al., 1996; Panagopoulos et al., 1996) . In each of the cases presently characterized the N-terminal domain of EWS contributes a strong transcription activation domain. Given the features of FEV, it will be interesting to test if the fusion of FEV with EWS converts a transcriptional repressor into an activator.
Materials and methods
Patients
MOU was a 2 year old girl presenting with a para spinal tumor. Pathological examination revealed a small round cell tumor staining positive for PAS and for MIC2 antigen but negative for desmin, neuron speci®c enolase and common leucocyte antigen. AUB was a 15 year old male with an extra-osseous maxillary tumor. Pathologically, this small round cell tumor was positive for vimentin but negative for PAS, desmin, common leucocyte antigen, S100 protein, neuron speci®c enolase, chromogranin and MIC2 antigen. Diagnosis for both tumors was compatible with that of extra-skeletal ET.
RNA and DNA isolation, Southern and Northern analysis
Total RNA was isolated from tumor material based on the acid guanidium-phenol chloroform method (Chomczynski and Sacchi, 1987) using the RNA-PLUS TM Kit from Bioprobe systems. DNA extraction, Southern blot, Northern blots and hybridization were performed according to standard procedures (Sambrook et al., 1989) . Human multiple tissues Northern blots were supplied by Clontech (USA).
PCR and RT ± PCR experiments
For reverse transcriptase PCR, 1 mg of total RNA was reverse-transcribed with random hexamers and PCR ampli®ed using the GeneAmp RNA PCR Kit (PerkinElmer Corp., Norwalk, CT) with the primers shown in Table 1 . In brief, 2 ml of cDNAs were submitted to 35 cycles of PCR ampli®cation consisting of denaturation for 30 s at 948C, variable annealing temperature for 1 min and elongation at 728C for 1 min, in a ®nal volume of 25 ml containing 1.5 mM MgCl 2 , 200 mM each dNTP and 500 nM of each primer with an automatic cycler (GeneAmp PCR system 9600; Perkin Elmer-Cetus Instruments, Norwalk, CT).
Long range PCR of genomic DNA was performed with the Expand TM Long Template PCR System (Boehringer, Mannheim, Germany) according to the manufacturer's procedure. In brief, ten initial cycles consisting of 10 s denaturation at 948C, 30 s annealing at 618C and 15 min elongation at 688C were performed, then followed by 20 cycles in which elongation time was progressively increased by 20 s at each cycle. The PCR mixture contained 350 mM of each dNTP, 1.75 mM MgCl 2 and 500 nM each primers.
Given the high GC content of the 5' end of the FEV cDNA, ampli®cation with primers FL and FLRB was performed using Expand TM Long Template PCR System with incorporation of 80% of 7-deaza dGTP (Boehringer Mannheim). The ampli®cation consisted of 35 cycles including denaturation at 948C for 20 s, annealing at 618C for 30 s and elongation at 688C for 2 min. PCR products were analysed on TBE agarose gels.
Cloning and sequencing of FEV cDNA and PCR products
A total of 10 6 phages from a lambda gt11 Ewing cDNA library oligo dT and random primed was screened with M3/F1 PCR product labeled with [a 32 P]dCTP. For sequencing, positive cDNAs were subcloned in the M13 phage vector and PCR products were puri®ed on Microcon 100 spin puri®cation columns (Amicon USA). All sequences were performed with Taq polymerase (ABI PRISM kit, Applied Biosystems), using¯uorescent primers or dideoxynucleotides, and analysed on an automatic 373A Applied Biosystems sequencer.
Chromosome localization of FEV was performed by PCR ampli®cation of somatic cell hybrid DNA (Coriell Institute for Medical Research, Camden, USA) using primers FJ and FK.
